Developer docs
API playgroundTry for free, no card

Search company profiles

Profound Medical

Full company profile

uuid0003c7a

Namestring
Profound Medical
Legal namestring
Profound Medical Corp.
Company typeenum
Public
Founded yearint
2009
Descriptiontext

Profound Medical Corp. is a commercial-stage Canadian medical device company that develops and markets MRI-guided, incision-free thermal ultrasound ablation systems for tissue treatment. Founded in 2008 and headquartered in Mississauga, Ontario, the company is publicly listed on NASDAQ (PROF) and TSX (PRN) and operates offices in Canada, the United States, Germany, and Finland, serving hospitals and urology practices across North America, Europe, the Middle East, and Oceania.

The company's two core platforms are TULSA-PRO, a robotically-driven transurethral ultrasound ablation system that combines real-time MR imaging, directional ultrasound, and proprietary closed-loop temperature feedback control for radiation-free treatment of prostate cancer and benign prostatic hyperplasia, and Sonalleve, an MR-HIFU (high-intensity focused ultrasound) platform acquired from Philips in 2017 for incision-free treatment of uterine fibroids, bone metastases pain palliation, osteoid osteoma, and desmoid tumors. Both platforms leverage the company's patented closed-loop thermal feedback algorithm, invented by COO Mathieu Burtnyk, with regulatory clearances spanning FDA 510(k), CE marking, China FDA, and FDA HDE.

The business operates a capital equipment razor-and-razorblade model: hospitals purchase TULSA-PRO systems (78 installed globally as of end-2025) and generate recurring high-margin consumables and procedure revenue (70%+ gross margins on consumables). The company markets directly through North American sales teams and via distribution partnerships in Canada (regained from Knight Therapeutics in November 2025), Saudi Arabia, and Australia/New Zealand, alongside strategic co-sales alliances with Siemens Healthineers, Philips, and GE Healthcare that bundle TULSA-PRO with the dominant MRI installed bases. CPT Category 1 reimbursement codes became effective in January 2025, and the CAPTAIN randomized controlled trial reported statistical superiority of TULSA over robotic radical prostatectomy in functional preservation outcomes in March 2026, materially strengthening the clinical and commercial case for adoption.

Short descriptiontext

Profound Medical is a Canadian commercial-stage medical device company that develops MRI-guided, incision-free thermal ultrasound ablation systems (TULSA-PRO for prostate disease and Sonalleve for uterine fibroids and bone metastases) sold to hospitals and urology practices globally under a capital-plus-consumables model.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersMississauga, Canada
HQ citystring
Mississauga
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
MRI-guided ablation systems, prostate cancer treatment, thermal ultrasound therapy, medical device manufacturing, minimally invasive surgery
Industry3 codes
PRIMARYHLAHABAG
Interventional Radiology & Image-Guided Therapy Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLAHADAN
Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHABAD
Ultrasound & Echography Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
MRI-Guided Medical Devices for Therapeutic Ablation
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1TULSA-PRO Capital Equipment Sales
TypeHardware Sales
Description

Sale of TULSA-PRO systems to hospitals and medical facilities with MRI suites. Q4 2025 capital sales reached US$3.7M driving installed base to 78 systems globally.

financialpost.com
2Procedure/Consumable Revenue
TypeHardware Sales
Description

Razor-and-razorblade model with procedure revenue from disposables and consumables used in TULSA procedures. Gross margins exceeding 70% on consumables.

defenseworld.net
3Sonalleve Platform Sales
TypeHardware Sales
Description

Sales of Sonalleve MR-HIFU systems for women's health (uterine fibroids) and oncology (bone metastases pain palliation) applications in markets where regulatory approved

stocktitan.net
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain
Pricing details1 tier
1TULSA-PRO System with 70%+ gross margin razor-and-razorblade model
ModelOtherBilling cadenceMulti-year contract
Notes

Capital equipment sales with high-margin consumables/revenue per procedure. Major insurance coverage expected by year-end 2026.

defenseworld.net
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1TULSA-PRO
Description

MRI-guided, robotically-driven transurethral thermal ultrasound system for customizable and predictable radiation-free ablation of prostate tissue while protecting urethra and rectum to preserve natural functional abilities.

profoundmedical.com
+3 more records
Core offering1 text field

Profound Medical develops and commercializes MRI-guided, incision-free tissue ablation systems. Its flagship TULSA-PRO® system uses real-time MR imaging combined with robotically-driven transurethral thermal ultrasound and closed-loop temperature feedback control to perform customizable, radiation-free ablation of prostate tissue for treating prostate cancer and BPH while preserving erectile function and urinary continence. The Sonalleve® MR-HIFU platform extends the same MRI-guided HIFU technology to incision-free treatment of uterine fibroids, adenomyotic tissue, osteoid osteoma, benign desmoid tumors, and palliative pain treatment of bone metastases. The company also offers AI-powered FDA-validated contouring software and operates a razor-and-razorblade business model with capital equipment sales complemented by high-margin (70%+) procedure consumables.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 50% of patients preserved both erectile function and urinary continence at 6 months vs 24% for robotic radical prostatectomy (CAPTAIN trial, 211 patients)
+5 more records
Product overview1 text field

Profound Medical develops and commercializes two core therapeutic platforms: TULSA-PRO® for men's health (prostate cancer and BPH treatment) and Sonalleve® for women's health and oncology (uterine fibroids and bone metastases pain palliation). Both platforms combine real-time MRI imaging, thermal ultrasound, and closed-loop temperature feedback control for radiation-free, incision-free tissue ablation. The TULSA-PRO system uses a transurethral (inside-out) approach while Sonalleve uses an external (outside-in) HIFU approach. The company also offers AI-powered contouring software tools for enhanced treatment planning and operates clinical evidence programs including the CAPTAIN randomized trial.

Product and service3 records
1TULSA-PRO®
CategoryMRI-Guided Prostate Ablation System
Description

MRI-guided, robotically-driven transurethral thermal ultrasound system for customizable, radiation-free ablation of prostate tissue. Combines real-time MR imaging, directional ultrasound, and closed-loop temperature feedback control for precise prostate cancer and BPH treatment while preserving natural functional abilities (erectile function and urinary continence). Treats prostates up to 250cc and supports up to 4 procedures per day. Sold to hospitals with MRI suites and urology practices, with high-margin consumables driving a razor-and-razorblade revenue model.

2Sonalleve® MR-HIFU Platform
CategoryMRI-Guided HIFU Ablation System
Description

MR-HIFU (Magnetic Resonance-guided High Intensity Focused Ultrasound) platform for incision-free ablation of uterine fibroids, adenomyotic tissue, and palliative treatment of bone metastases pain. Uses external ultrasound delivery through intact skin with real-time MRI temperature monitoring and control. Also indicated for treatment of osteoid osteoma (U.S. FDA HDE) and management of benign desmoid tumors (EU CE marked). Sold to women's health centers, oncology centers, and hospitals with MRI suites.

3AI-Powered Contouring Tools
CategoryAI Treatment Planning Software
Description

FDA-validated AI software tools for automated treatment planning and contouring in TULSA procedures, enabling more efficient and consistent physician workflow as a software add-on to TULSA-PRO.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-05-15
Description

Letters of intent to pursue collaboration on use of PSMA-PET imaging agents (Gozellix and Illuccix) with MRI-guided TULSA procedures. Focus on patient selection, treatment planning, and post-treatment monitoring. Initiative aims to accelerate adoption of novel therapeutic workflows and generate clinical evidence for personalized prostate cancer care.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-11-10
Description

Former exclusive Canadian distributor agreement (April 2015 - November 2025) ended as Knight refocused on pharmaceuticals. Profound paid CDN$90,000 (US$64,000) one-time payment plus 5% royalty on Canadian Net Sales for 15 years. Profound regained exclusive distribution rights effective November 2025.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-12-02
Description

Definitive co-sales and co-marketing agreement to commercialize combined MRI-guided prostate therapy solution pairing Profound's TULSA-PRO system with Siemens Healthineers' Magnetom Free.Max MR scanner. Companies expect to initiate sales of 'total prostate solution' in 2025 pending compatibility testing. CMS placement at Urology APC Level 7 supports economic case for adoption.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-12-21
Description

Strategic agreement to expand provider access to TULSA-PRO (December 2020). Partnership for market access with GE's diagnostic imaging installed base.

5Royal Philips
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-06-30
Description

Definitive agreement to expand collaboration and acquire Sonalleve MR-HIFU business (June 2017). Philips previously partnered on sales/marketing (2016) and joint development (2015). Sonalleve table designed compatible with Philips MRI systems.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2016-02-29
Description

Strategic agreement with Siemens to further development of prostate cancer care (February 2016). Forms foundation for ongoing collaboration leading to 2024 co-sales agreement.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

EDAP TMS offers Focal One, a robotic HIFU platform for prostate tissue ablation, making it the most direct competitor to Profound's TULSA-PRO. Both companies target localized prostate cancer with non-invasive/incision-free ablation workflows and compete on similar clinical outcomes and reimbursement positioning.

TypeDirect peer
Description

InSightec markets ExAblate, an MR-guided focused ultrasound system for uterine fibroids, bone metastases pain palliation, and other indications — directly comparable to Profound's Sonalleve MR-HIFU platform. Both companies are the two principal players in clinical MR-guided HIFU worldwide.

TypeBroad incumbent
Description

Intuitive Surgical's da Vinci robotic platform is the dominant treatment for radical prostatectomy — the comparator arm in Profound's CAPTAIN trial. While not a direct ablation competitor, it is the incumbent modality TULSA-PRO must displace in urology purchasing decisions and clinical guidelines.

TypeBroad incumbent
Description

Stryker acquired Profound CEO Arun Menawat's previous company (Novadaq Technologies) for ~$701M, giving it fluoroscopic imaging and surgical visualization. Stryker is a broad interventional/surgical device incumbent whose urology, ENT, and surgical visualization portfolios overlap with Profound's hospital call points.

TypeBroad incumbent
Description

Boston Scientific has a large urology and pelvic health franchise (formerly Endo Pharmaceuticals/AMS) competing for the same hospital budgets and urology practice mindshare as TULSA-PRO. As a broad medtech incumbent, it offers alternative BPH and prostate treatment options and adjacent capital equipment.

TypeEmerging player
Description

AngioDynamics offers NanoKnife irreversible electroporation and other ablation technologies used in urology and oncology. It competes for the same focal/partial ablation procedures as TULSA-PRO in prostate and other soft-tissue indications, though with a different energy modality.

TypeBroad incumbent
Description

Hologic is a leader in women's health, including fibroid treatment (Acessa / Sonata radiofrequency ablation) and gynecologic surgical offerings. It overlaps directly with Sonalleve's uterine fibroid indication and competes for the same gynecology purchasing channels.

TypeBroad incumbent
Description

Medtronic is a broad medtech incumbent with significant urology, surgical, and ablation portfolios (e.g., Emprint, Cool-tip RF ablation, InterStim). It competes for hospital capital equipment budgets and ablation procedure share across overlapping indications.

TypeEmerging player
Description

CONMED offers electrosurgical, ablation, and general surgery instruments used in urology and other specialties. While smaller in scale than the broad incumbents, it provides alternative energy-based tissue ablation devices that compete for the same hospital capital and procedure budgets.

TypeEmerging player
Description

Merit Medical provides interventional radiology and oncology products, including ablation and image-guided therapy accessories. It is a relevant adjacent peer selling into the same interventional radiology and oncology hospital call points as TULSA-PRO and Sonalleve.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds15 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Profound Medical

MRI-Guided Medical Devices for Therapeutic Ablationprofoundmedical.com

Profound Medical is a Canadian commercial-stage medical device company that develops MRI-guided, incision-free thermal ultrasound ablation systems (TULSA-PRO for prostate disease and Sonalleve for uterine fibroids and bone metastases) sold to hospitals and urology practices globally under a capital-plus-consumables model.

What Profound Medical does

Profound Medical Corp. is a commercial-stage Canadian medical device company that develops and markets MRI-guided, incision-free thermal ultrasound ablation systems for tissue treatment. Founded in 2008 and headquartered in Mississauga, Ontario, the company is publicly listed on NASDAQ (PROF) and TSX (PRN) and operates offices in Canada, the United States, Germany, and Finland, serving hospitals and urology practices across North America, Europe, the Middle East, and Oceania.

The company's two core platforms are TULSA-PRO, a robotically-driven transurethral ultrasound ablation system that combines real-time MR imaging, directional ultrasound, and proprietary closed-loop temperature feedback control for radiation-free treatment of prostate cancer and benign prostatic hyperplasia, and Sonalleve, an MR-HIFU (high-intensity focused ultrasound) platform acquired from Philips in 2017 for incision-free treatment of uterine fibroids, bone metastases pain palliation, osteoid osteoma, and desmoid tumors. Both platforms leverage the company's patented closed-loop thermal feedback algorithm, invented by COO Mathieu Burtnyk, with regulatory clearances spanning FDA 510(k), CE marking, China FDA, and FDA HDE.

The business operates a capital equipment razor-and-razorblade model: hospitals purchase TULSA-PRO systems (78 installed globally as of end-2025) and generate recurring high-margin consumables and procedure revenue (70%+ gross margins on consumables). The company markets directly through North American sales teams and via distribution partnerships in Canada (regained from Knight Therapeutics in November 2025), Saudi Arabia, and Australia/New Zealand, alongside strategic co-sales alliances with Siemens Healthineers, Philips, and GE Healthcare that bundle TULSA-PRO with the dominant MRI installed bases. CPT Category 1 reimbursement codes became effective in January 2025, and the CAPTAIN randomized controlled trial reported statistical superiority of TULSA over robotic radical prostatectomy in functional preservation outcomes in March 2026, materially strengthening the clinical and commercial case for adoption.

Profound Medical firmographics

Firmographics
Name
Profound Medical
Legal name
Profound Medical Corp.
Website
https://profoundmedical.com
Company type
Public
Founded year
2009
Operating status
Operating
Headcount range
101–250 employees
Short description
Profound Medical is a Canadian commercial-stage medical device company that develops MRI-guided, incision-free thermal ultrasound ablation systems (TULSA-PRO for prostate disease and Sonalleve for uterine fibroids and bone metastases) sold to hospitals and urology practices globally under a capital-plus-consumables model.
Ownership category
akta.pro rank

Profound Medical industry classification

Industry
Product category
MRI-Guided Medical Devices for Therapeutic Ablation
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHABAG
Interventional Radiology & Image-Guided Therapy Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLAHADAN
Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHABAD
Ultrasound & Echography Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment

Keywords

  • MRI-guided ablation systems
  • Prostate cancer treatment
  • Thermal ultrasound therapy
  • Medical device manufacturing
  • Minimally invasive surgery

Where Profound Medical is headquartered

Location

Headquarters

HQ city
Mississauga
HQ country
Canada
HQ region
North America

Offices4 records

Markets served

Profound Medical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain

Revenue model

  1. TULSA-PRO Capital Equipment Sales: Sale of TULSA-PRO systems to hospitals and medical facilities with MRI suites. Q4 2025 capital sales reached US$3.7M driving installed base to 78 systems globally.
  2. Procedure/Consumable Revenue: Razor-and-razorblade model with procedure revenue from disposables and consumables used in TULSA procedures. Gross margins exceeding 70% on consumables.
  3. Sonalleve Platform Sales: Sales of Sonalleve MR-HIFU systems for women's health (uterine fibroids) and oncology (bone metastases pain palliation) applications in markets where regulatory approved

Pricing tiers

ModelBillingPrice
OtherMulti-year contractTULSA-PRO System with 70%+ gross margin razor-and-razorblade model

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Profound Medical product offering

Product offering

Core offering

Profound Medical develops and commercializes MRI-guided, incision-free tissue ablation systems. Its flagship TULSA-PRO® system uses real-time MR imaging combined with robotically-driven transurethral thermal ultrasound and closed-loop temperature feedback control to perform customizable, radiation-free ablation of prostate tissue for treating prostate cancer and BPH while preserving erectile function and urinary continence. The Sonalleve® MR-HIFU platform extends the same MRI-guided HIFU technology to incision-free treatment of uterine fibroids, adenomyotic tissue, osteoid osteoma, benign desmoid tumors, and palliative pain treatment of bone metastases. The company also offers AI-powered FDA-validated contouring software and operates a razor-and-razorblade business model with capital equipment sales complemented by high-margin (70%+) procedure consumables.

Product overview

Profound Medical develops and commercializes two core therapeutic platforms: TULSA-PRO® for men's health (prostate cancer and BPH treatment) and Sonalleve® for women's health and oncology (uterine fibroids and bone metastases pain palliation). Both platforms combine real-time MRI imaging, thermal ultrasound, and closed-loop temperature feedback control for radiation-free, incision-free tissue ablation. The TULSA-PRO system uses a transurethral (inside-out) approach while Sonalleve uses an external (outside-in) HIFU approach. The company also offers AI-powered contouring software tools for enhanced treatment planning and operates clinical evidence programs including the CAPTAIN randomized trial.

Differentiator

Problem solved

Functional benefit

Brands

  • TULSA-PRO: MRI-guided, robotically-driven transurethral thermal ultrasound system for customizable and predictable radiation-free ablation of prostate tissue while protecting urethra and rectum to preserve natural functional abilities.
  • Sonalleve
  • TULSA Procedure
  • PRO-Talk Academy

Products and services

  • TULSA-PRO® MRI-guided, robotically-driven transurethral thermal ultrasound system for customizable, radiation-free ablation of prostate tissue. Combines real-time MR imaging, directional ultrasound, and closed-loop temperature feedback control for precise prostate cancer and BPH treatment while preserving natural functional abilities (erectile function and urinary continence). Treats prostates up to 250cc and supports up to 4 procedures per day. Sold to hospitals with MRI suites and urology practices, with high-margin consumables driving a razor-and-razorblade revenue model.
  • Sonalleve® MR-HIFU Platform MR-HIFU (Magnetic Resonance-guided High Intensity Focused Ultrasound) platform for incision-free ablation of uterine fibroids, adenomyotic tissue, and palliative treatment of bone metastases pain. Uses external ultrasound delivery through intact skin with real-time MRI temperature monitoring and control. Also indicated for treatment of osteoid osteoma (U.S. FDA HDE) and management of benign desmoid tumors (EU CE marked). Sold to women's health centers, oncology centers, and hospitals with MRI suites.
  • AI-Powered Contouring Tools FDA-validated AI software tools for automated treatment planning and contouring in TULSA procedures, enabling more efficient and consistent physician workflow as a software add-on to TULSA-PRO.

Quantifiable outcome

  • 50% of patients preserved both erectile function and urinary continence at 6 months vs 24% for robotic radical prostatectomy (CAPTAIN trial, 211 patients)
  • +5 more outcomes

Companies that use Profound Medical

Customer profile

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Profound Medical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Profound Medical partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered minor and core.

  • Telix PharmaceuticalsminorStrategic or Co-development Partner · 15 May 2026Letters of intent to pursue collaboration on use of PSMA-PET imaging agents (Gozellix and Illuccix) with MRI-guided TULSA procedures. Focus on patient selection, treatment planning, and post-treatment monitoring. Initiative aims to accelerate adoption of novel therapeutic workflows and generate clinical evidence for personalized prostate cancer care.
  • Knight Therapeutics Inc.minorChannel Partner/ Reseller/ Distributor · 10 November 2025Former exclusive Canadian distributor agreement (April 2015 - November 2025) ended as Knight refocused on pharmaceuticals. Profound paid CDN$90,000 (US$64,000) one-time payment plus 5% royalty on Canadian Net Sales for 15 years. Profound regained exclusive distribution rights effective November 2025.
  • Siemens HealthineerscoreStrategic or Co-development Partner · 2 December 2024Definitive co-sales and co-marketing agreement to commercialize combined MRI-guided prostate therapy solution pairing Profound's TULSA-PRO system with Siemens Healthineers' Magnetom Free.Max MR scanner. Companies expect to initiate sales of 'total prostate solution' in 2025 pending compatibility testing. CMS placement at Urology APC Level 7 supports economic case for adoption.
  • GE HealthcareminorStrategic or Co-development Partner · 21 December 2020Strategic agreement to expand provider access to TULSA-PRO (December 2020). Partnership for market access with GE's diagnostic imaging installed base.
  • Royal PhilipscoreStrategic or Co-development Partner · 30 June 2017Definitive agreement to expand collaboration and acquire Sonalleve MR-HIFU business (June 2017). Philips previously partnered on sales/marketing (2016) and joint development (2015). Sonalleve table designed compatible with Philips MRI systems.
  • Siemens (Strategic Agreement)coreStrategic or Co-development Partner · 29 February 2016Strategic agreement with Siemens to further development of prostate cancer care (February 2016). Forms foundation for ongoing collaboration leading to 2024 co-sales agreement.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Profound Medical competitors and assessment

Company assessment

Direct peers

  • EDAP TMS: EDAP TMS offers Focal One, a robotic HIFU platform for prostate tissue ablation, making it the most direct competitor to Profound's TULSA-PRO. Both companies target localized prostate cancer with non-invasive/incision-free ablation workflows and compete on similar clinical outcomes and reimbursement positioning.
  • InSightec: InSightec markets ExAblate, an MR-guided focused ultrasound system for uterine fibroids, bone metastases pain palliation, and other indications — directly comparable to Profound's Sonalleve MR-HIFU platform. Both companies are the two principal players in clinical MR-guided HIFU worldwide.

Broad incumbents

  • Intuitive Surgical: Intuitive Surgical's da Vinci robotic platform is the dominant treatment for radical prostatectomy — the comparator arm in Profound's CAPTAIN trial. While not a direct ablation competitor, it is the incumbent modality TULSA-PRO must displace in urology purchasing decisions and clinical guidelines.
  • Stryker Corporation: Stryker acquired Profound CEO Arun Menawat's previous company (Novadaq Technologies) for ~$701M, giving it fluoroscopic imaging and surgical visualization. Stryker is a broad interventional/surgical device incumbent whose urology, ENT, and surgical visualization portfolios overlap with Profound's hospital call points.
  • Boston Scientific: Boston Scientific has a large urology and pelvic health franchise (formerly Endo Pharmaceuticals/AMS) competing for the same hospital budgets and urology practice mindshare as TULSA-PRO. As a broad medtech incumbent, it offers alternative BPH and prostate treatment options and adjacent capital equipment.
  • Hologic: Hologic is a leader in women's health, including fibroid treatment (Acessa / Sonata radiofrequency ablation) and gynecologic surgical offerings. It overlaps directly with Sonalleve's uterine fibroid indication and competes for the same gynecology purchasing channels.
  • Medtronic: Medtronic is a broad medtech incumbent with significant urology, surgical, and ablation portfolios (e.g., Emprint, Cool-tip RF ablation, InterStim). It competes for hospital capital equipment budgets and ablation procedure share across overlapping indications.

Emerging players

  • AngioDynamics: AngioDynamics offers NanoKnife irreversible electroporation and other ablation technologies used in urology and oncology. It competes for the same focal/partial ablation procedures as TULSA-PRO in prostate and other soft-tissue indications, though with a different energy modality.
  • CONMED: CONMED offers electrosurgical, ablation, and general surgery instruments used in urology and other specialties. While smaller in scale than the broad incumbents, it provides alternative energy-based tissue ablation devices that compete for the same hospital capital and procedure budgets.
  • Merit Medical Systems: Merit Medical provides interventional radiology and oncology products, including ablation and image-guided therapy accessories. It is a relevant adjacent peer selling into the same interventional radiology and oncology hospital call points as TULSA-PRO and Sonalleve.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Profound Medical social profiles

Digital presence

Profound Medical compliance and trust

Trust signal

Compliance5 records

Profound Medical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Profound Medical leadership team

Management profile

Number of profiles

Profiles9 records

Profound Medical funding detail

Funding detail

Funding overview

Funding rounds15 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Profound Medical M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Profound Medical

What does Profound Medical do?

Profound Medical develops and commercializes MRI-guided, incision-free tissue ablation systems. Its flagship TULSA-PRO® system uses real-time MR imaging combined with robotically-driven transurethral thermal ultrasound and closed-loop temperature feedback control to perform customizable, radiation-free ablation of prostate tissue for treating prostate cancer and BPH while preserving erectile function and urinary continence. The Sonalleve® MR-HIFU platform extends the same MRI-guided HIFU technology to incision-free treatment of uterine fibroids, adenomyotic tissue, osteoid osteoma, benign desmoid tumors, and palliative pain treatment of bone metastases. The company also offers AI-powered FDA-validated contouring software and operates a razor-and-razorblade business model with capital equipment sales complemented by high-margin (70%+) procedure consumables.

Is Profound Medical a public or private company?

Profound Medical is a public company. It is classified as public and is currently operating.

When was Profound Medical founded?

Profound Medical was founded in 2009. It employs 101 to 250 people.

Where is Profound Medical based?

Profound Medical is headquartered in Mississauga, Canada, in the North America region.

How does Profound Medical make money?

Three revenue lines are on record. TULSA-PRO Capital Equipment Sales are the primary driver. The others are procedure/Consumable Revenue and sonalleve Platform Sales.

Who are Profound Medical's main competitors?

Direct peers on record are EDAP TMS and InSightec. Broad incumbents are Intuitive Surgical, Stryker Corporation, Boston Scientific, Hologic and Medtronic. Emerging players are AngioDynamics, CONMED and Merit Medical Systems.

Does Profound Medical have an API?

No public API is recorded for Profound Medical.

What industry is Profound Medical in?

Profound Medical's product category is MRI-Guided Medical Devices for Therapeutic Ablation. Its primary akta.pro industry code is HLAHABAG, Interventional Radiology & Image-Guided Therapy Systems, with a secondary code of HLAHADAN, Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools). Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Yahoo3 Canadian AI Healthcare Stocks With Up To 53% Revenue GrowthThree Canadian AI healthcare stocks are profiled: Profound Medical, WELL Health Technologies, and Perimeter Medical Imaging AI. Profound Medical reported $9.83 million in Q3 2026 revenue, while WELL Health Technologies generates over CA$2.6 billion annually. Perimeter Medical Imaging AI has about $2 million in revenue and significant losses.TradingViewProfound Medical names Richard Fabian CEO; Arun Menawat to become Executive ChairmanProfound Medical appointed Richard Fabian as CEO effective January 15, 2027, and Arun Menawat as Executive Chairman, stepping down from CEO. Fabian, previously CEO of FUJIFILM Sonosite, will become a non-voting Board observer, while Menawat continues as a Board member. The company also appointed Jason Mills as director and Matthew Sobczyk as CFO.YahooProfound Medical to Participate in the Stifel 2026 Healthcare ConferenceProfound Medical Corp. announced that President Richard Fabian will present at the Stifel 2026 Healthcare Conference on November 12, 2026, in NYC. The presentation will be broadcast live and archived, and executives will also meet with investors. The company's iMRI technologies include TULSA-PRO for prostate ablation and Sonalleve for pain palliation.GlobeNewswireProfound Medical to Participate in the Stifel 2026 Healthcare ConferenceProfound Medical Corp. announced that President Richard Fabian will present at the Stifel 2026 Healthcare Conference on November 12, 2026, in NYC. The presentation will be broadcast live and archived, and executives will also meet with investors. The company's iMRI technologies include TULSA-PRO for prostate ablation and Sonalleve for pain palliation.FinancialContent Business PageProfound Medical to Participate in the Stifel 2026 Healthcare ConferenceProfound Medical Corp. announced that President Richard Fabian will present at the Stifel 2026 Healthcare Conference on November 12, 2026, in NYC. The presentation will be broadcast live and archived, and executives will also meet with investors. The company's iMRI technologies include TULSA-PRO for prostate ablation and Sonalleve for pain palliation.American Banking and Market NewsWhat Profound Medical (PROF) Said on Its Q3 Earnings CallProfound Medical reported Q3 revenue of $9.8 million, up 86% year-over-year, and raised its full-year revenue outlook to at least $25 million. The company has 98 TULSA-PRO systems installed and reached its 5,000th procedure, with a $79.2 million pipeline. CEO Arun Menawat will step down in January 2027.MarketBeatWhat Profound Medical (PROF) Said on Its Q3 Earnings CallProfound Medical reported Q3 revenue of $9.8 million, up 86% year-over-year, and raised its full-year revenue outlook to at least $25 million. The company has 98 TULSA-PRO systems installed and expects to fund operations for at least 12 months without raising capital.YahooProfound Medical Corp (PROF) (Q3 2026) Earnings Call Highlights: Revenue Surges 86% as Pipeline ...Profound Medical reported Q3 2026 revenue up 86% and a $79.2 million pipeline, with gross margins targeted at 70-75%. The company expects ASC reimbursement impact in H2 next year and is focusing on commercial growth and operational efficiency.Simply Wall StTop 3 Canadian AI Healthcare Stocks To Watch In November 2026Three Canadian AI healthcare stocks—Telescope Innovations, Profound Medical, and Perimeter Medical Imaging AI—are profiled for November 2026. Telescope generates CA$7.3M, Profound $19M, and Perimeter $2.1M, with market caps of CA$26M, CA$362M, and CA$27.6M respectively. All are loss-making, and execution around adoption and funding is highlighted.YahooProfound Medical (PROF) Reports Q3 Loss, Beats Revenue EstimatesProfound Medical reported a Q3 loss of $0.21 per share, beating the consensus estimate of $0.19, and posted revenues of $9.83 million, up 0.31% from estimates. The company has topped revenue estimates twice in the last four quarters, while shares have lost about 9% year-to-date versus the S&P 500's gain of 12.3%.